Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Orencia Abatacept Arthritis, rheumatoid List with clinical criteria and/or conditions Complete
Orfadin nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete
Orgovyx relugolix Advanced prostate cancer Reimburse with clinical criteria and/or conditions Complete
Orilissa elagolix Moderate to severe pain associated with endometriosis Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation Do not reimburse Complete
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Do not reimburse Complete
Orladeyo berotralstat hereditary angioedema (HAE) Reimburse with clinical criteria and/or conditions Complete
Osphena ospemifene Dyspareunia, vaginal dryness Reimburse with clinical criteria and/or conditions Complete
Otezla Apremilast Plaque psoriasis Do not list Complete
Otezla Apremilast Arthritis, psoriatic List with criteria/condition Complete